{"id":"NCT04068051","sponsor":"Axsome Therapeutics, Inc.","briefTitle":"Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)","officialTitle":"An Open-Label, Long-Term Study to Assess the Safety and Efficacy of AXS-07 (MoSEICâ„¢ Meloxicam and Rizatriptan) for the Acute Treatment of Migraine in Adults","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-07-06","primaryCompletion":"2020-09-22","completion":"2020-09-22","firstPosted":"2019-08-28","resultsPosted":"2023-10-10","lastUpdate":"2023-10-10"},"enrollment":706,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"AXS-07","otherNames":[]}],"arms":[{"label":"AXS-07","type":"EXPERIMENTAL"}],"summary":"MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.","primaryOutcome":{"measure":"Long-term Safety of Chronic Intermittent Use of AXS-07","timeFrame":"Up to 12 months","effectByArm":[{"arm":"AXS-07","deltaMin":293,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":51,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":706},"commonTop":["Nausea","Vomiting","Dizziness"]}}